The first "China Liver Disease Management and Comprehensive Prevention and Control of Liver Cancer" Summit Forum was held

On April 21, 2021, the first "China Liver Disease Management and Integrated Liver Cancer Prevention and Control" summit forum was held in Wuxi.
Based on the city’s “early screening and integrated prevention and control of liver cancer” demonstration project practice, regional liver disease management and integrated liver cancer prevention and control were released.
Mode: Relying on the national cancer prevention and control strategy and the application of world-class innovative technology for early screening, a comprehensive management chain of "technology upgrade, community screening, hospital referral, treatment follow-up" is realized
.
At the same time, the China Hepatitis Prevention and Control Foundation will launch the "Chronic Liver Disease Prevention and Cure" project with an expert group review, and promote the popularization of innovative early screening technologies for liver cancer and the "Liver Disease Management and Liver Cancer" through the release of expert consensus and the establishment of a continuing education mechanism for first-line doctors.

The first "China Liver Disease Management and Comprehensive Prevention and Control of Liver Cancer" summit forum was hosted by the Huishan District People's Government of Wuxi City, and hosted by the Huishan Economic Development Zone Management Committee and the leading domestic precision medical institution Genetron Biotech
.
Yang Xizhong, executive vice chairman of the China Hepatitis Prevention Foundation, Li Ni, deputy director of the Office of Early Cancer Diagnosis and Treatment of the National Cancer Center, and Fang Li, head of Wuxi Huishan District People's Government, attended and delivered speeches

Liver cancer is one of the most common cancers in China, and nearly half of the world's liver cancers occur in China
.
Due to the long-term lack of reliable screening technology, most patients are already in the middle and late stages once they are diagnosed, and the prime time for treatment has been missed

The regional demonstration project of "Early Liver Cancer Early Screening and Comprehensive Prevention and Control" in Huishan District, Wuxi City, under the guidance of the National Cancer Center, was successfully launched in November last year to provide high-risk groups with liquid biopsy-based early liver cancer screening and testing
.
Up to now, many patients have detected early liver cancer and received rapid diagnosis and treatment in the city's project partner hospital

Wuxi takes "striving to meet the new expectations of the people for a better life and innovating to implement healthy city actions" as an important starting point, and always regards the advancement of cancer diagnosis and treatment as an important connotation of all-round health services for people's livelihood
.
With the joint efforts of the National Cancer Center, China Hepatitis Prevention Foundation, hospitals and industry experts, with Genetron Health's self-developed precision screening technology for liver cancer as a strong support, the joint development covers the early screening of liver cancer as a guide, integrating "prevention-diagnosis" The precision medicine vertical industry chain ecosystem integrated with "-treatment" will build a life-cycle scientific and technological liver protection umbrella for the people of Wuxi, and provide a new benchmark model for liver cancer prevention and control for "Healthy China"

Fang Li, Chief of Huishan District, Wuxi City, expressed his affirmation of the results of the demonstration project in his speech: "The national cancer prevention and control strategy and Genetron Health Early Screening innovative technology will empower the'liver cancer early screening comprehensive prevention and control' demonstration project, creating cancer.
The new scientific and technological anti-cancer model that integrates screening and diagnosis and treatment has provided the people in the jurisdiction with better all-round and full-cycle early liver cancer screening and diagnosis and health management services.
The key indicators of regional cancer prevention have reached the domestic advanced level
.
"

Yang Xizhong, executive vice chairman of the China Hepatitis Prevention Foundation, said: “The China Hepatitis Prevention Foundation initiated the “Chronic Liver Disease Prevention and Treatment Project” for the prevention and treatment of liver disease to liver cancer.
The China Hepatitis Prevention Foundation has always insisted on focusing on prevention and combining prevention and treatment.
Policy
.
We will work with multidisciplinary experts on liver cancer to form a multidisciplinary treatment plan and expert consensus for the prevention and treatment of liver cancer in the population with chronic liver disease.

As an important part of the summit forum, on the same day, the China Hepatitis Prevention Foundation and Genetron Health jointly held the "Expert Consensus on Hepatocellular Carcinoma Surveillance" kick-off meeting, inviting more than 30 well-known domestic experts in related fields, including academician Zhuang Hui of the Chinese Academy of Engineering.

Li Ni, deputy director of the Office of Cancer Early Diagnosis and Treatment of the National Cancer Center, said in his speech: “In order to reduce the mortality rate of cancer, the most important thing is to implement suitable screening and early diagnosis and treatment of key and high-incidence cancers
.
We propose to increase by 5 The annual survival rate, as a main indicator of the effectiveness of cancer prevention and control, directly reflects the effects of cancer prevention and control in China.

       The Demonstration Project of "Integrated Prevention and Control of Early Liver Cancer Screening" uses the HCCscreen™, a liquid biopsy product for early screening of liver cancer jointly developed by the National Cancer Center and Genetron Health
.
In the forum, Dr.
Hu Yunfu, Chief Medical Officer of Genetron Health, gave an in-depth interpretation of his latest results: As of February 2021, Genetron Health had completed the follow-up of 1,615 hepatitis B surface antigen-positive patients, and HCCscreen™ achieved 88% sensitivity and The specificity of 93% is higher than that of ultrasound combined with alpha-fetoprotein (AFP) detection
.
In the latest prospective cohort study, 49% of liver cancer patients diagnosed by HCCscreen™ are in the early stage with tumors less than 3 cm
.

       The excellent performance of HCCscreen™ for early tumor screening has also been strongly confirmed in the "Prevention and Control of Early Liver Cancer Screening" demonstration project
.
At the scene, the patient who found early-stage tumors through community screening shared the experience: the patient tested positive by HCCscreen™ on December 23, 2020, went to the hospital for examination on the 25th, confirmed the presence of a 25x28mm tumor in the liver, and performed surgery on the 28th , Completed the treatment on December 30 and was discharged from the hospital.
The prognosis is good now
.

       Qiu Yuanwang, deputy dean of Wuxi Fifth People’s Hospital, introduced the primary liver cancer screening and diagnosis and treatment management plan.
Based on the technology of early screening of liver cancer by liquid biopsy, the realization of "diagnosis within three days and treatment within seven days" for patients with early liver cancer is to grasp the early stage.
The golden window period for liver cancer treatment is included in the liver cancer lifelong monitoring plan to implement early diagnosis and treatment of liver cancer
.

       Zhou Xiaojiang, Senior Vice President of Akcome Group, said in his speech: “The future of physical examination will make full use of innovative technologies such as big data, artificial intelligence, and precision medicine to achieve earlier detection, earlier diagnosis, and earlier treatment
.
Akcome will be introduced in 2019.
Genetron Health has obtained the HCCscreen ^TM product recognized by the US FDA as a "breakthrough medical device" for early screening of liver cancer because of its recognition of Genetron Health's original liquid biopsy technology with international cutting-edge advantages
.
Last month, we just found out A case of early liver cancer less than 3 cm, the patient is only 45 years old, and is at the golden age of life
.
After timely detection and treatment, a five-year survival rate of 90% may be achieved
.
He can quickly return to work and life, and return to his family By your side
.
We believe that the age of medical examinations for algorithmic medical treatment through innovative technology has come, and it will bring more accurate medical examinations and medical services to Chinese people
.
"

       In order to better undertake liver cancer early screening comprehensive prevention and control demonstration projects and major national special R&D projects, Genetron Health has established a cancer early screening center headquarters base in Wuxi (Huishan) Life Science and Technology Industrial Park to create advanced early screening R&D, testing operations and The testing product manufacturing base, including internationally advanced clinical testing laboratories, medical device production workshops, R&D laboratories and data analysis platforms, has a total area of ​​more than 10,000 square meters
.
On the same day, the base officially started construction and is expected to be put into operation at the end of the year.
It will load a new high-energy engine for the Wuxi precision medical characteristic industrial base, and benefit the people with more new formats and new models of big health
.

       Wang Sizhen, co-founder and CEO of Genetron Health, expressed his confidence in the application of Genetron Health’s early screening technology and his strategic vision to create a vertical ecological chain for liver cancer: “Genetic Health has always been committed to solving cancer through the most efficient methods and technological breakthroughs.
This is the number one enemy that plagues human health
.
We are very happy to see that the early liver cancer screening technology jointly developed by Genetron Health and the National Cancer Center is at the forefront of the world with its excellent data performance and achieved through participating in the government’s comprehensive cancer prevention and control demonstration project.
Effective practice in large-scale population applications, working with Wuxi medical institutions and business partners including Akcome Group and Chia Tai Tianqing Pharmaceutical Group to jointly explore a new prevention and control model that integrates cancer screening and diagnosis and treatment, and Recognized by industry experts
.
Genetron Health will continue to deepen its technological innovation and product transformation.
With its strong R&D strength in early screening technology and a complete full-cycle service system, it will contribute to the reduction of urban liver cancer mortality and the improvement of national health
.
"